| Literature DB >> 35116966 |
Ying Chen1,2, Yunchao Huang1,2, Huanqi Ning1, Xianmeng Chen1, Xiangxiu Tan1, Xiaojie Ding1,2.
Abstract
BACKGROUND: Lung cancer induced by burning coal can be etiologically and clinically different from lung cancer caused by smoking. Despite previous work, the gene fusion patterns in lung cancer patients affected by household coal combustion still deserve further study.Entities:
Keywords: ALK; Non-small cell lung cancer (NSCLC); ROS1; gene fusion; household coal combustion; reverse transcription-polymerase chain reaction (RT-PCR)
Year: 2019 PMID: 35116966 PMCID: PMC8799241 DOI: 10.21037/tcr.2019.09.37
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
The primer sets for detection of gene rearrangements
| Gene and variant | Sequence |
|---|---|
| Forward: 5'-GTGCAGTGTTTAGCATTCTTGGGG-3' | |
| Reverse: 5'-TCTTGCCAGCAAAGCAGTAGTTGG-3' | |
| Forward: 5'-GTCAGCTCTTGAGTCACGAGTT-3' | |
| Reverse: 5'-TCTTGCCAGCAAAGCAGTAGTTGG-3' | |
|
| Forward: 5'-TCGGCAACTTTAGCGAGTA-3' |
| Reverse: 5'-GGACACCTGGCCTTCATAC-3' | |
|
| Forward: 5'-ATGTATGACAACATGTCCAC-3' |
| Reverse: 5'-TCAGGGCCCAGGCTGGTTCA-3' | |
|
| Forward: 5'-TCGTTTATTGGATAGCTTGGAACCAC-3' |
| Reverse: 5'-TCTTGCCAGCAAAGCAGTAGTTGG-3' | |
| Forward: 5'-CTTACTGATAAACTCAAGGAGGCAGAGAC-3' | |
| Reverse: 5'-ACCTCGCAGCTCAGCCAACT-3' | |
| Forward: 5'-CAGGACCTCCTAGAAGGCCGATAC-3' | |
| Reverse: 5'-CATCCATTATCTTCAGCTTTCTCCCACT-3' | |
| Forward: 5'-ACCCGTTGAAGAGAGTGAGGATG-3' | |
| Reverse: 5'-TGAAGTGCTCTTTCTTATCTCAAGG-3' | |
| Forward: 5'-AGGATGTGTCCAACAAGGTGTCAATG-3' | |
| Reverse: 5'-TAATCTTCTATGCCAGACAAAGGTCAGTG-3' | |
| Forward: 5'-GTGCTGCTTGCTGTGTGGCT-3' | |
| Reverse: 5'-CTACATCCATTATCTTCAGCTTTCTCCCA-3' | |
| Forward: 5'-GGATGCACCATTGGCTCCTGTT-3' | |
| Reverse: 5'-CATTATCTTCAGCTTTCTCCCACTGTATTG-3' | |
| Forward: 5'-GGATGCACCATTGGCTCCTGTT-3' | |
| Reverse: 5'-CTCTTTGTCTTCGTTTATAAGCACTGTCAC-3' | |
| Forward: 5'-AAAGGAGAGAAACCGTGGAGAGAG-3' | |
| Reverse: 5'-GCCAGACAAAGGTCAGTGGGATT-3' | |
| LRIG3-ROS1 (E17/E35) | Forward: 5'-GACCAACTTGCCAGCAGATATTCCT-3' |
| Reverse: 5'-ACCTCGCAGCTCAGCCAACT-3' | |
| GOPC-ROS1 (E7:E35) | Forward: 5'-CGTAGAGTATGAAGATGAGAGTGGACAT-3' |
| Reverse: 5'-ACCTCGCAGCTCAGCCAACT-3' | |
| CCDC6-RET | Forward: 5'-GCTGGAGACCTACAAACTGA-3' |
| Reverse: 5'-CCTTGACCACTTTTCCAAATTC-3' | |
|
| Forward: 5'-TAAGGAAATGACCAACCACCAG-3' |
| Reverse: 5'-CCTTGACCACTTTTCCAAATTC-3' | |
|
| Forward: 5'-CTCCCAAGCCTGTGAGCAAGAT-3' |
| Reverse: 5'-GTTGTGGCACTCAGCAAGGAAG-3' |
Clinic-pathological characteristics of 205 NSCLC patients
| Variables | NSCLC patients (n=205) |
|---|---|
| Average age (years) | 57 (range, 38–82) |
| Gender, n (%) | |
| Male | 116 (56.6) |
| Female | 89 (43.4) |
| Histology, n (%) | |
| Adenocarcinoma | 159 (77.6) |
| Squamous carcinoma | 46 (22.4) |
| Tumor stage, n (%) | |
| I | 98 (47.8) |
| II | 43 (21.0) |
| IIIA | 52 (25.4) |
| IIIB–IV | 12 (5.9) |
| Ex- or current smoker, n (%) | |
| Yes | 96 (46.8) |
| No | 109 (53.2) |
| HCU, n (%) | |
| Yes | 112 (54.6) |
| No | 93 (45.4) |
| ALK rearrangement, n (%) | |
| EML4-ALK | 18 (8.8) |
| Negative | 187 (91.2) |
| ROS rearrangement, n (%) | |
| CD74-ROS1 | 5 (2.4) |
| Negative | 200 (97.6) |
NSCLC, non-small cell lung cancer.
Figure 1Clinic-pathological characteristics of 205 NSCLC patients. (A) Patients age distribution. No apparent age difference was observed between smokers and never smokers, but coal users developed lung cancer much earlier than never coal users. When evaluated by overall exposure (tobacco and coal), union set patients developed lung cancer earlier than double-negative subjects. If double-positive subjects were considered separately, they were the earliest to develop lung cancer. (B) Patients gender distribution. There was no apparent gender imbalance on coal using, but never smokers were 17% in male and 100% in female, so the union set had more males, while the double-negative group included more females. (C) Patients histology. AD was the dominate histology in all subgroups, only smokers had statistically more SCC. (D) Patients stage distribution. There were more stage IIIA and IIIB–IV cases in smokers and HCU patients. Combining both factors, patients in union set had increased stage IIIA–IV case (59.3%), if double-positive subjects were selected out, 60.3% of them were in stage IIIA–IV. (E) When age, stage, smoking was considered together, increased smokers were found in stage IIIA–IV. (F) HCU patients were younger in all the stages and had a higher ratio in stage IIIA–IV. (G) Double-negative subjects were mainly in stage I–II with relatively older age. Union set patients covered large age span (range, 40–82 years), showed clearly early-onset and made the majority of stage IIIA–IV cases. Double-positive patients were mainly found in stage IIIA–IV with wider age span (range, 38–75 years). (H) Distribution of 13 Asian studies on ALK fusions according to gender rate and smoking rate. X axis: male/female rate, Y axis: smoking: never/ever rate, and the bubble size means positive rate of ALK fusions in that study. For Asian patients, most ALK+ subjects featured with higher rate of females and nonsmokers, but the ALK+ rate in these subject populations were relatively lower (upper-left quadrant, 8 smaller bubbles). On the other hand, studies found higher male rate in ALK+ cases seemed to have increased ALK+ rate in their subject populations (upper-right quadrant, 3 larger bubbles). One Japanese study located directly on the Y axis. Present study (red bubble) set in a quadrant with few co-existing works, potentially indicating special population composition. *, P<0.05. AD, adenocarcinoma; SCC, squamous cell carcinoma; HCU, household coal user; smoker and HCU/coal-user, double-positive subjects; never smoker and never coal-user, double-negative subjects; smoker or HCU/coal-user, union set of smokers and coal users.
Clinic-pathological characteristics of NSCLC patients with different exposure
| Variables | Smoker (n=96) | P | HCU (n=112) | P | Smoker or HCU (n=145) | P | Smoker and HCU (n=63) | P |
|---|---|---|---|---|---|---|---|---|
| Average age (years) | 58 | 54 | 56 | 54 | ||||
| Gender, n (%) | 5.6E-32 | 0.11 | 6.5E-10 | 6.6E-17 | ||||
| Male | 96 (82.8) | 69 (59.5) | 102 (87.9) | 63 (54.3) | ||||
| Female | 0 (0.0) | 43 (48.3) | 43 (48.3) | 0 (0.0) | ||||
| Histology, n (%) | 0.012 | 0.70 | 0.37 | 0.16 | ||||
| Adenocarcinoma | 67 (42.1) | 88 (55.3) | 110 (69.2) | 45 (28.3) | ||||
| Squamous carcinoma | 29 (63.0) | 24 (52.2) | 35 (76.1) | 18 (39.1) | ||||
| Tumor stage, n (%) | – | – | – | – | ||||
| I | 35 (35.7) | 36 (36.7) | 58 (59.2) | 13 (13.3) | ||||
| II | 16 (37.2) | 24 (55.8) | 28 (65.1) | 12 (27.9) | ||||
| IIIA | 36 (69.2) | 40 (76.9) | 47 (90.4) | 29 (55.8) | ||||
| IIIB–IV | 9 (75.0) | 12 (100.0) | 12 (100.0) | 9 (75.0) | ||||
| ALK fusion, n (%) | 0.44 | 0.048 | 0.027 | 0.43 | ||||
| EML4-ALK | 10 (55.6) | 14 (77.8) | 17 (94.4) | 7 (38.9) | ||||
| Negative | 86 (46.0) | 98 (52.4) | 128 (68.4) | 56 (29.9) | ||||
| ROS fusion, n (%) | 0.37 | 0.065 | 0.32 | 1.0 | ||||
| CD74-ROS1 | 1 (20.0) | 5 (100.0) | 5 (100.0) | 1 (20.0) | ||||
| Negative | 95 (47.5) | 107 (53.5) | 140 (70.0) | 62 (31.0) |
The percentage is calculated based on the total number of each variable listed on the left side. P value behind each subgroup is calculated between this subgroup and its complementary set. P value calculated by chi-square test or Fisher’s exact test, when there is at least a cell frequency less than 5; % is the ratio in certain type of variables; Smoker or HCU means union set of smoker and coal user; Smoker and HCU means double-positive subjects, being a smoker and coal user at the same time. NSCLC, non-small cell lung cancer; HCU, household coal user.
Clinic-pathological characteristics of gene rearrangements detected by RT-PCR in 205 NSCLC patients
| Variables | ALK rearrangements, n (%) | ROS1 rearrangements, n (%) | |||||
|---|---|---|---|---|---|---|---|
| Positive | Negative | P | Positive | Negative | P | ||
| Total number of patients | 18 (8.8) | 187 (91.2) | 5 (2.4) | 200 (97.6) | |||
| Gender | 0.93 | 0.17 | |||||
| Male | 10 (8.6) | 106 (91.4) | 1 (0.9) | 115 (99.1) | |||
| Female | 8 (9.0) | 81 (91.0) | 4 (4.5) | 85 (95.5) | |||
| Age, years | 0.062 | 0.16 | |||||
| <55 | 11 (13.3) | 72 (86.7) | 4 (4.8) | 79 (95.2) | |||
| ≥55 | 7 (5.7) | 115 (94.3) | 1 (0.8) | 121 (99.2) | |||
| Histology | 0.015 | 0.59 | |||||
| Adenocarcinoma | 18 (11.3) | 141 (88.7) | 5 (3.1) | 154 (96.9) | |||
| Squamous cell carcinoma | 0 (0.0) | 46 (100.0) | 0 (0.0) | 46 (100.0) | |||
| Stage | 0.42 | 0.58 | |||||
| I | 10 (10.2) | 88 (89.8) | 3 (3.1) | 95 (96.9) | |||
| II | 2 (4.7) | 41 (95.3) | 0 (0.0) | 43 (100.0) | |||
| IIIA | 6 (11.5) | 46 (88.5) | 2 (3.8) | 50 (96.2) | |||
| IIIB–IV | 0 (0.0) | 12 (100.0) | 0 (0.0) | 12 (100.0) | |||
| Smoking history | 0.44 | 0.37 | |||||
| Yes (current or ex-smoker) | 10 (10.4) | 86 (89.6) | 1 (1.0) | 95 (99.0) | |||
| Never | 8 (7.3) | 101 (92.7) | 4 (3.7) | 105 (96.3) | |||
| Household coal use | 0.048 | 0.065 | |||||
| Yes (current or ex-user) | 14 (12.5) | 98 (87.5) | 5 (4.5) | 107 (95.5) | |||
| Never | 4 (4.3) | 89 (95.7) | 0 (0.0) | 93 (100.0) | |||
| Overall exposure (tobacco and coal) | 0.027 | 0.32 | |||||
| Smoker or household coal-user | 17 (11.7) | 128 (88.3) | 5 (3.4) | 140 (96.6) | |||
| Never smoker & never coal-user | 1 (1.7) | 59 (98.3) | 0 (0.0) | 60 (100.0) | |||
The percentage is calculated based on the total number of each variable listed on the left side. P value calculated by chi-square test or Fisher’s exact test, when there is at least a cell frequency less than 5; smoker or household coal-user: union set of smoker and coal user; never smoker & never coal-user: double-negative patient, not a smoker and also not a coal user. NSCLC, non-small cell lung cancer; RT-PCR, reverse transcriptase polymerase chain reaction; ALK, anaplastic lymphoma kinase; ROS1, ROS proto-oncogene 1.
Clinic-pathological characteristics of 18 NSCLC patients with ALK rearrangements
| No. | Gender | Age | Pathology diagnosis | Stage | Smoking history | Household coal combustion | ALK fusion genes detected by RT-PCR |
|---|---|---|---|---|---|---|---|
| 1 | F | 46 | AD | I | N | Y | EML4-ALK V1 |
| 2 | M | 43 | AD | I | Y | Y | EML4-ALK V1 |
| 3 | M | 61 | AD | IIIA | Y | N | EML4-ALK V1 |
| 4 | M | 54 | AD | II | Y | Y | EML4-ALK V1 |
| 5 | F | 53 | AD | I | N | Y | EML4-ALK V3a + V3b |
| 6 | M | 47 | AD | IIIA | Y | Y | EML4-ALK V3a + V3b |
| 7 | F | 57 | AD | II | N | Y | EML4-ALK V3a + V3b |
| 8 | F | 60 | AD | IIIA | N | Y | EML4-ALK V3a + V3b |
| 9 | M | 64 | AD | IIIA | Y | N | EML4-ALK V3a + V3b |
| 10 | M | 44 | AD | I | Y | Y | EML4-ALK V3a + V3b |
| 11 | F | 50 | AD | I | N | Y | EML4-ALK V3a + V3b |
| 12 | M | 53 | AD | I | Y | Y | EML4-ALK V3a + V3b |
| 13 | F | 45 | AD | I | N | Y | EML4-ALK V3a + V3b |
| 14 | M | 58 | AD | IIIA | Y | Y | EML4-ALK V3a + V3b |
| 15 | M | 62 | AD | IIIA | Y | N | EML4-ALK V3a + V3b |
| 16 | M | 38 | AD | I | Y | Y | EML4-ALK V3a + V3b |
| 17 | F | 59 | AD | I | N | N | EML4-ALK V3a + V3b |
| 18 | F | 45 | AD | I | N | Y | EML4-ALK V3a + V3b |
NSCLC, non-small cell lung cancer; AD, adenocarcinoma; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein-like 4; RT-PCR, reverse transcription polymerase chain reaction; M, male; F, female; Y, yes; N, no; V1, variant 1; V3a, variant 3a; V3b, variant 3b.
Clinic-pathological characteristics of 5 NSCLC patients with ROS1 rearrangements
| No. | Gender | Age | Pathology diagnosis | Stage | Smoking history | Household coal combustion | ROS1 fusion genes detected by RT-PCR |
|---|---|---|---|---|---|---|---|
| 1 | F | 66 | AD | IIIA | N | Y | CD74-ROS1 (E6/E34) |
| 2 | F | 48 | AD | IIIA | N | Y | CD74-ROS1 (E6/E34) |
| 3 | F | 50 | AD | I | N | Y | CD74-ROS1 (E6/E34) |
| 4 | F | 51 | AD | I | N | Y | CD74-ROS1 (E6/E34) |
| 5 | M | 42 | AD | I | Y | Y | CD74-ROS1 (E6/E34) |
NSCLC, non-small cell lung cancer; RT-PCR, reverse transcription polymerase chain reaction; ROS1, ROS proto-oncogene 1; M, male; F, female; E6, exon6; E34, exon34; AD, adenocarcinoma.
Investigation of 18 ALK rearrangement reports in non-small cell lung cancer
| No. | Study or subgroup (reference No.) | Ethnic group | Subjects sources | Fusion gene type | Gender distribution (male/female) | Smoking history (ever/never) | Number of subjects in each variant type | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | |||||||
| 1 | Shinmura | Asian | Japan (n=77) | EML4-ALK (n=2) | 1/1 | 2/0 | 1 | 1 | – | – | – | – | – | – |
| 2 | Inamura | Asian | Japan (n=221) | EML4-ALK (n=5) | 2/3 | 2/3 | 2 | 3 | – | – | – | – | – | – |
| 3 | Koivunen | Asian | Korea (n=167) | EML4-ALK (n=8) | 3/5 | 2/6 | 2 | – | 4 | 2 | – | – | – | – |
| 4 | Takeuchi | Asian | Japan (n=363) | EML4-ALK (n=11) | 5/6 | 1/10 | 3 | 3 | 3 | 1 | 1 | – | – | – |
| 5 | Takeuchi | Asian | Japan (n=130) | EML4-ALK (n=7); KIF5B-ALK (n=1) | NA | NA | 1 | 1 | 3 | – | – | 1 | 1 | – |
| 6 | Wong | Asian | China (n=266) | EML4-ALK (n=13) | 5/8 | 1/12 | 2 | 2 | 8 | – | 1 | – | – | – |
| 7 | Takahashi | Asian | Japan (n=313) | EML4-ALK (n=5)b | 1/4 | 1/4 | 1 | – | 2 | – | – | – | – | – |
| 8 | Zhang | Asian | China (n=103) | EML4-ALK (n=12) | 7/5 | 2/10 | 4 | 1 | 3 | – | 1 | 3 | – | – |
| 9 | Jin | Asian | Korea (n=167) | EML4-ALK (n=10) | 4/6 | 3/7 | 8 | – | 2 | – | – | – | – | – |
| 10 | Li | Asian | China (n=208) | EML4-ALK (n=7) | 0/7 | 1/6 | 2 | 1 | 4 | – | – | – | – | – |
| 11 | Wu | Asian | China (n=312) | EML4-ALK (n=12); KIF5B-ALK (n=1) | 4/8 | 5/7 | 3 | 1 | 8 | – | – | – | – | – |
| 12 | Wang | Asian | China(n=430) | EML4-ALK (n=62)c; KIF5B-ALK (n=2) | 25/21 | 17/29 | 24 | 8 | 30 | – | – | – | – | – |
| 13 | Shan | Asian | China(n=297) | EML4-ALK (n=37)d | 20/17 | 9/22 (6: NA) | – | – | – | – | – | – | – | – |
| Total for Asian | – | 3,054 | 195 | 77/91 | 46/116 | 53 | 21 | 67 | 3 | 3 | 4 | 1 | – | |
| 14 | Lin | Caucasian | USA (n=106) | EML4-ALK (n=12) | NA | NA | 11 | – | – | – | – | – | – | 1 |
| 15 | Martelli | Caucasian | Italy and Spain (n=120) | EML4-ALK (n=9) | 8/1 | 8/1 | 7 | – | 2 | – | – | – | – | – |
| 16 | Sanders | Caucasian | USA (n=55) | EML4-ALK (n=5) | NA | NA | 1 | – | 3 | – | – | – | – | 1 |
| 17 | Hofman | Caucasian | France (n=154) | EML4-ALK (n=4)d | 0/4 | 0/4 | – | – | – | – | – | – | – | – |
| 18 | Wallander | Caucasian | USA (n=46) | EML4-ALK (n=11)e | 11/5 | NA | 9 | – | 2 | – | – | – | – | – |
a, there were overlapping in the subject sources, so the data were shown as combined together; b, two of the 5 subjects positive for EML4-ALK had no variant type data (the authors considered them to be novel types); c, EML4-ALK variant types were detected by RT-PCR, characteristics of patients were reported based on FISH results; d, the study did not give the data of EML4-ALK variant types; e, 11 subjects positive for EML4-ALK had variant type data, the other 5 was identified by FISH. EML4, echinoderm microtubule-associated protein-like 4; ALK, anaplastic lymphoma kinase; KIF5B, kinesin family member 5B; RT-PCR, reverse transcription polymerase chain reaction; FISH: fluorescence in situ hybridization; NA: Data not included in the report; V1, variant 1; V2, variant 2; V3, variant 3; V4, variant 4; V5, variant 5; V6, variant 6; V7, variant 7; V8, variant 8.